Key clinical point: Low expression of human epidermal growth factor receptor 2 (HER2) protein was associated with improved survival outcomes in patients with early breast cancer (BC).
Major finding: HER2-low expression vs HER2-zero BC was associated with a significant overall survival benefit in the entire population (hazard ratio [ HR] 0.83; 95% CI 0.78-0.88 ) and in the subpopulations of patients with hormone receptor-positive BC ( HR 0.83; 95% CI 0.77-0.89 ) and triple-negative BC ( HR 0.78; 95% CI 0.70-0.87 ).
Study details: Findings are from a meta-analysis of 14 studies including 52,106 patients with early BC.
Disclosures: This study was funded by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.
Source: Wei T et al. Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis. Front Oncol. 2023; 13:1100332 (Feb 2). Doi: 10.3389/fonc.2023.1100332